ImmunityBio Shares Rise on ANKTIVA Surge, Saudi Approval for Lung Cancer
The performance highlights a pivot to full-scale commercialization across multiple regions.
Overview
- ImmunityBio stock climbed 15.73% to $10.81 after the company detailed accelerating sales and global rollout for ANKTIVA.
- Full-year 2025 net product revenue reached $113 million, with a 20% sequential increase in the fourth quarter.
- ANKTIVA demand strengthened sharply, with a 700% jump in net product revenue and a 750% rise in unit sales year over year.
- Regulatory clearances now span 33 countries across the U.S., EU, U.K. and Saudi Arabia, including an EU conditional approval for BCG‑unresponsive bladder cancer.
- Saudi Arabia issued the first approval for ANKTIVA with checkpoint inhibitors in metastatic non‑small cell lung cancer, with a launch in the Kingdom expected within about 60 days.